Back

Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial

26 August 2018 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 3 - Cardiac patients with comorbidities Antidiabetic Pharmacotherapy ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)

5 More presentations in this session

Presentation thumbnail
Professor J. Seufert (Freiburg, DE)
Abstract Slides
Presentation thumbnail
Professor S. Bain (Swansea, GB)
Abstract Slides
Presentation thumbnail
Professor C. Lang (Dundee, GB)
Abstract
Presentation thumbnail
Ms M. Panahi (London, GB)
Abstract Slides
Presentation thumbnail
Professor S. Martsevich (Moscow, RU)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 3 - Cardiac patients with comorbidities

The Event

Event poster

ESC Congress 2018

26 August 2018 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular outcomes across GLP-1/GIP agonists in a large, diverse real-world cohort: the INCRETIN-CV study
29 August 2026
thumbnail
ESC TV Today
Episode 26: Lp(a): the future starts now - Myocardial infarction in older age and frailty
6 November 2025
thumbnail
Congress Presentation
Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes
1 September 2025
thumbnail
Congress Presentation
GLP-1-ra and heart failure-related outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis.
23 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources